01498 PURAPHARM
- 0.780
- 0.0000.00%
PURAPHARM News
培力農本方：2023年度報告
China's modern medicine leads public health for the first time at Puli Farming Expo
Hong Kong, April 22, 2024 /Mainland Community/ -- On April 13, 2024, Puli Agricultural Company Limited (HKEX: 1498, hereinafter referred to as “Pili Farming Party”) will make its debut as an exhibitor at the First China International Consumer Fair (hereinafter referred to as “Consumer Expo”), one of the four largest national trade fairs in China. With its unique brand charm, it will be the focus of this exhibition. The HKTDC will relaunch its inaugural exhibition, which will promote the internationalisation strategy of the agricultural sector in line with the theme of “sharing open opportunities and creating a better life together”.
Pelinon's side (01498.HK): Termination of placement agreement
Pelinong (01498.HK) announced that on April 12, 2024 (after the trading period), the placement agent delivered a written notice of termination to terminate the placement agreement in accordance with the terms of the placement agreement. Upon termination of the placement agreement, all of the obligations of each party to the placement agreement will be terminated and no party shall bring any claim against the other party with respect to any matter or event arising out of or relating to the placement agreement, except for any prior violator of any obligation under the placement agreement.
Multiple arrows in unison! Pharmaceutical innovation support policies are coming
Recently, many places, including Beijing, Guangzhou, and Zhuhai, have successively issued relevant policies (draft for comments) to support the high-quality development of the biomedical industry or innovative pharmaceutical devices. The intensive introduction of support policies and the tight schedule have attracted great attention from the industry.
Express News | Guojin Securities: Focus on opportunities such as in vitro diagnostic collection clean-up and proprietary Chinese medicine collection
Express News | Capital Securities: The high dividend rate in the Chinese medicine industry is stable and sustainable
PuraPharm's Net Loss Shrinks in 2023; Revenue Falls 9%
PuraPharm Corporation (HKG:1498) saw a decline in attributable loss for the year ended Dec. 31, 2023, to HK$106.1 million from HK$120.2 million during the year-ago period, a filing posted on the Hong
Pelinong (01498) plans to sell a maximum of 50 million shares at a 6.02% discount to raise about HK$37.7 million
Peilinong (01498) issued an announcement. On March 28, 2024, the company and the placement agent signed an placement agreement...
Peilinong Benfang (01498) announced 2023 results. Net loss of HK$106 million narrowed 11.76% year over year
Pelinong Benfang (01498) announced its 2023 results, with revenue of approximately HK$407 million, a year-on-year decrease of 9.2%...
PURAPHARM: ANNOUNCEMENT OF FINAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
PURAPHARM: POSTPONEMENT OF BOARD MEETING
Pelinong Group (01498.HK) plans to hold a board meeting on March 25 to approve the annual results
Glonghui, March 13, 丨 Pelinong (01498.HK) announced that the board of directors meeting will be held on March 25, 2024 (Monday) to consider and approve, as appropriate, the Group's annual results results for the year ended 31 December 2023, publish an announcement of the annual results, and consider payment of a final dividend (if any).
PURAPHARM: NOTICE OF BOARD MEETING
Express News | Debon Securities: Traditional Chinese medicine allocation is cost-effective, focus on small and medium capitalization stocks that have overfallen
Express News | China Post Securities: The valuation of the Chinese medicine sector is currently at a low level
R&D investment from listed Chinese medicine companies continues to rise, and the development of innovative traditional Chinese medicine drugs enters the “fast track” |Chinese medicine 2024 outlook
Financial Services Association, Feb. 21 (Reporters Zhang Liangde and Wang Pingan) In recent years, in the context of national policies supporting development, traditional Chinese medicine companies are facing unprecedented development opportunities.
Express News | Wanlian Securities: The overall valuation level of the Chinese medicine industry is at a historically low level
Medical insurance relief restrictions for traditional Chinese medicine injections to open a 100 billion market? |Traditional Chinese Medicine 2024 Outlook
① An industry insider told the Financial Federation reporter: “As restrictions on some varieties of traditional Chinese medicine injections are lifted, the market may reach 100 billion in the next few years.” ② In addition to the acceleration of sales in the traditional Chinese medicine injection market due to medical insurance restrictions, the return to normal in-hospital diagnosis and treatment services in the post-pandemic era is also beneficial to the increase in overall injection market sales.
Traditional Chinese medicine formula market development accelerates collection and starts industry “big fish eat small fish” ahead of schedule | Traditional Chinese medicine 2024 outlook
Financial Services Association, Feb. 18 (Reporters Zhang Liangde and Wang Pingan) Due to the continuous entry of new players after the completion of the pilot (policy) of the traditional Chinese medicine formula industry and the “unexpected advance” of collection in 15 provinces, the traditional Chinese medicine formula granule market pattern may face reshaping. Some industry insiders said that the industry may enter the “big fish eat small fish” stage.
CICC: The pharmaceutical sector has entered the value investment range. It is recommended to focus on overseas exports and opportunities to increase the localization rate
CICC released a research report saying that after more than 2 years of systematic adjustments, the pharmaceutical sector has entered the value investment range.
Analysis
Price Target
No Data
